New regen-cov™ (casirivimab and imdevimab) data show supportive results in patients hospitalized with covid-19

Tarrytown, n.y., sept. 30, 2021 /prnewswire/ --  trial met primary endpoint, showing regen-cov significantly reduced viral load within 7 days of treatment; trial conducted in patients hospitalized with covid-19 who did not require high-flow oxygen or mechanical ventilation at baseline numeric improvements with regen-cov observed for all clinical endpoints, including a 36% reduced risk of death by day 29 in the overall population, increasing to 56% reduced risk in patients who were seronegative at baseline similar efficacy observed with both doses (2,400 mg and 8,000 mg); u.s. fda is currently reviewing request to add treatment in hospital settings to regen-cov authorization regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that a trial assessing investigational regen-cov™ (casirivimab and imdevimab) in patients hospitalized with covid-19 met its primary endpoint.
REGN Ratings Summary
REGN Quant Ranking